http://rdf.ncbi.nlm.nih.gov/pubchem/patent/PT-95230-B

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7550a62e34c0d46b867127dee5002c8d
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-35
filingDate 1990-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 1997-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber PT-95230-B
titleOfInvention USING RAPAMICINE AND / OR ITS DERIVATIVES AND / OR ITS DERIVATIVES AND / OR PRE-PHARMACIES IN THE PRODUCTION OF PHARMACEUTICAL COMPOSITIONS FOR INHIBITING THE REJECTION OF TRANSPLANTS OF ORGAOS OR FABRICS IN MAMMALS.
abstract The invention relates to the process for the preparation of pharmaceutical compositions to prevent the rejection of organ or organic tissue transplants in a mammal which needs said transplant, comprising the mixing of at least [3S-[3R*(1R*, 3S*, 4S*)] 6S*, 7E*, 9S*, 10S*, 14R*, 15E*, 17E, 19E, 21R*, 23R*, 26S*, 27S*, 34BR*]]-9, 10, 12, 13, 14, 21, 22, 23, 24, 25, 26, 27, 32, 33, 34, 34B-hexadeca- hydro-9,27-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclo- hexyl)-1-methylethyl]-10, 21-dimethoxy-6,8, 12,14,20,26- hexamethyl-23,27-epoxy-3H-pyrido[2,1-C][1,4]oxazacyclo- hentriacontino-1,5,11,28,29(4H,6H,31H)pentone (rapamycin), of the formula <IMAGE> and/or one of the derivatives thereof and/or pre-drugs thereof, if necessary with one or more other chemotherapeutic agents which also act as inhibitors of the rejection of organ and tissue transplants, with pharmaceutically acceptable vehicular and/or auxiliary substances, in a proportion preferably between 0.01 and 15% by weight of active ingredient. The scope of the invention also embraces a process to prevent the rejection of organ or tissue transplants in a mammal, which involves the administration to said mammal of a) a quantity of rapamycin, in combination with b) a quantity of one or more other chemotherapeutic agents in order to inhibit the rejection of the transplant, for example azathioprine, corticosteroids, cyclosporin and FK506, the combined quantities of a) and b) being effective for inhibition of transplant rejection and maintenance of this inhibition.
priorityDate 1990-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID9606
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID26066
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419507527
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID9606
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3037032
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419506776
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2265
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419588607
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5284616
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID408245893
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5284373
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457754985
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID410862584
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID137319715
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419551199
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2909
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414853227
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID57465615

Total number of triples: 31.